



KENNY C. GUINN
Governor

STATE OF NEVADA
DEPARTMENT OF HUMAN RESOURCES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

**Nevada Medicaid
Pharmacy & Therapeutics Committee**

Location of Meeting

401 South Carson Street, Room 2135, Carson City, NV

Teleconference

555 E. Washington, Room 4406 Las Vegas, NV

MEETING MINUTES OF

June 17, 2004

1:00 p.m.

Committee Members Carson City:

Steven Phillips, MD, Chairman
Judy Britt, PharmD
Carl Heard, MD
Larry Pinson, PharmD
Susan Pinter, MD

Committee Members in Las Vegas:

Diana Bond, RPh
Linda Flynn, RPh
Robert Horne, MD
Thomas Wiser, PharmD

Absent: Alan Greenberg, MD

Others Present:

Carson City:

Darrell Faircloth AGO, Coleen Lawrence DHFCP, Nancy Davis DHCFP, Jeff Monaghan PharmD First Health Services Corporation, Dawn Daly RPh First Health Services Corporation, Jamie Wyels RPh First Health Services Corporation, Joe Tyler Advisory Committee, Bert Jones GSK, Tom Wood Wyeth, Roland Baldwin Wyeth, Cosimo Costa Wyeth, Rosetta Johnson HPD, Jeff Hill Lilly, B. Eliot Cole MD American Academy of Pain Management, Steve Schaerer Astra-Zeneca, Dean McAlicster Astra-Zeneca, Jackie Blossy 3M, Jeanette Belz Nevada Psychiatric Association, Jake Mater Aventis, Tom Mahony Pfizer, Joseph Schwab Novartis, Paul Pereira Tap, Tina Lina Shire, Jim Goddard Shire, Chris Lepore Johnson & Johnson, Joann Phillips, Tom Taylor Purdue, Jim Morgan Novartis, Tracy Davies Lilly

Las Vegas:

Carla Sloan Advisory Committee, Paul Patel Ortho-McNeil, Don Roberts UMC, Ron Taylor Ortho-McNeil, Dick Krospel Abbott, Coleen Fong BMS, Jennifer Lauper BMS, Paul Pereira Tap, Emerald Foster Nevada Care, Dee Dee VanWorner Pfizer, Bos Mendes Pfizer, Catherine Harris Pfizer, Sondra Rohac Bayer, Jeanette Belz Astra Zeneca, Roland Baldwin Wyeth, Kirk Huffner Nevada, Harvey Roseberg Resource Pharmacy, Sedrick Spencer Roche.

I. Call to Order and Roll Call

Chairman Steven Phillips called the meeting to order at 1:00 p.m. Committee members present in Las Vegas: Diana Bond, RPh, Linda Flynn, RPh, Robert Horne, MD and Thomas Wiser, PharmD. Members present in Carson City: Steven Phillips, MD, Judy Britt, PharmD, Carl Heard, MD, Larry Pinson, PharmD and Susan Pinter, MD.

II. Approval of Minutes of May 27, 2004 Meeting

Page 2 correction: Jamie Wyels, FHSC, did an overview of dihydropyridines and nondihydropyridines.

Page 3 Item 4 correction: Doug Ethel was present with Dr. Stoloff.

Page 4 correction: change to "Dr. Wiser accepted the friendly amendment".

Page 6 correction: agenda item VIII- change to "atorvastatin"

Motion to Accept with changes: Dr. Wiser

Seconded: Dr. Horne

Ayes: Unanimous

Motion Carried

III. Sedative Hypnotics

Public Comment:

Las Vegas:

Maria CousCous-Sanofi, Gave an overview of Ambien.

Dr. Phillips asked if Ambien was on the VA formulary. She responded it was not on the VA's national formulary. Dr. Wiser asked about comparative studies. She responded there were some studies with Restoril that showed same efficacy in improving sleep quality.

Carson City:

Dr. Monaghan reviewed the bylaws regarding identification of speakers and their disclosures of any funding or grants they have received.

Dr. Monaghan, FHSC, gave an overview of the class.

Dr. Pinson asked about safety in pregnancy. Dr. Monaghan stated benzodiazepines are pregnancy category X, Ambien is category B, and Sonata is category C. Dr. Britt asked about quantity per prescription. Dr. Monaghan stated there is a concern with excessive utilization and this concern will be brought to the Drug Use Review Board at the June 24th meeting. Dr. Horne stated that Halcion is not available as 0.5mg and should be 0.25mg.

Motion: Dr. Pinson moved all drugs in this class are therapeutic alternatives.

Seconded: Dr. Heard

Dr. Horne asked to consider pregnancy when the list is brought forward.

Vote: Ayes: Unanimous

Motion carried.

IV. New Generation Antidepressants

Public Comment:

Rosetta Johnson-Letter attached.

Dr. Heard asked if she represented anyone else beside herself. She stated only her son.

Las Vegas:

None

Carson City:

Tom Wood, Wyeth, introduced Dr. Costa, Wyeth- He gave an overview of Effexor XR. Brian String, GSK introduced Geraldine Steinagel, MD, private practice, with affiliations with Pfizer, Lilly and GSK. She gave an overview of Wellbutrin XL.

Dr.Horne asked if Zyban was in the XL form. The response was no.

Ms. Daly, FHSC, stated written comments have been provided to the committee members.

Ms. Daly, FHSC, gave an overview of the class.

Dr. Britt asked about the black box warning for Serzone. Ms. Daly responded it is not marketed in Europe, Canada, New Zealand and Australia and BMS plans on discontinuing it in the United States. Dr. Horne stated that 90% of the prescriptions for trazodone are probably for the sedative/hypnotic effect not for the treatment of depression.

Dr. Britt expressed concerns regarding Serzone due to the black box warning.

Motion: Dr. Horne motioned this class be therapeutically equivalent with the following exceptions: bupropion immediate release, maprotiline, nefazodone, and venlafaxine immediate release be excluded from the PDL.

Seconded: Dr. Wiser

Dr. Pinson asked for clarification.

Dr. Horne made the amendment to change the verbiage from excluded to non-preferred.

Seconded: Dr Wiser

Judy Britt stated that Effexor IR has been used for vasomotor symptoms associated with menopause in the smaller doses. Dr. Horne asked if there was a smaller dose than 37.mg extended release. The response was yes; it comes in 25mg.

Vote: Ayes: Dr. Phillips, Ms. Flynn, Dr. Horne, Ms. Bond, Dr. Wiser, Naves; Dr. Pintar, Dr. Pinson, Dr. Heard, Dr. Britt

Motion did not carry.

Darrell Faircloth, Deputy Attorney General, stated that six votes were needed to carry the motion.

Dr. Horne asked what the four committee members who voted no would like to see. Dr. Britt stated she would like to have Effexor IR available, otherwise she was in agreement. Dr. Heard stated he would like to leave the field as open as possible until First Health Services comes back with its recommendations.

Motion: Dr. Heard motioned for the class to be considered therapeutic alternatives with the following exceptions being non-preferred: nefazodone and maprotiline.

Seconded: Dr. Pintar

Ayes: Dr. Pintar, Dr. Phillips, Dr. Britt, Dr. Pinson, Dr. Heard, Dr. Horne, Ms. Flynn

Naves: Ms.Bond, Dr. Wiser

Motion carried.

V. Serotonin Reuptake Inhibitors

Public Comment:

Las Vegas:

Dr. Childress, board certified psychiatrist, private practice. Her pharmaceutical affiliations included Pfizer, Shire, Soltec Novartis, Lilly, Astra-Zeneca and Johnson & Johnson. Dr. Childress stated she was there on behalf of her patients not a pharmaceutical manufacturer. She then gave an overview of all SSRIs.

Dr. Eric Dubay, GSK-Gave an overview of Paxil CR.

Mazzie Maxs, Pfizer-Gave an overview of Zoloft-Attachment.

Dr. Horne asked if they were studies for the treatment of general anxiety disorder. The response was there have been studies showing Zoloft is effective in treating generalized

anxiety disorder but it is going off patent soon and the company will not be pursuing that indication.

Kevin Forrest Pharmaceutical-Gave an overview of Lexapro.

Dr. Horne asked if there were any studies involving Lexapro 30mg currently underway. Mr. Forrest responded yes, there were.

Carson City:

Ms. Daly, FHSC, stated written comments have been provided to the committee members.

Ms. Daly, FHSC gave an overview of the class.

Dr. Wiser expressed concerns about the use in pregnancy and lactation. Ms. Daly responded that the benefits should outweigh the risks. . If the patient is breastfeeding then the prescriber should suggest a discontinuance of breastfeeding if the medication is truly needed.

Motion: Dr. Horne motioned that as a class fluoxetine, sertraline, paroxetine, citalopram and escitalopam be considered therapeutically equivalent and that First Health Services recommend a pediatric choice.

Seconded: Ms Bond

Vote: Ayes: Dr. Pintar, Dr. Phillips, Dr. Pinson, Ms. Bond, Dr. Horne, Dr. Wiser, Ms. Flynn

Naye: Ms. Britt, Dr. Heard

Motion carried

Recess

VI. CNS Stimulants/ADHD Agents

Public Comment:

Las Vegas:

Dr. John Pinto, sleep specialist, stated he was not representing Cephalon, but has done work for them. He then gave an overview of Provigil.

Dr. Heard said the literature states Provigil has euphoric and stimulant side effects. Dr. Pinto stated it has some but not as much as the stimulants.

Dr. Stanton Smith, board certified psychiatrist, stated he has done some speaking for Pfizer. He gave a comparison of stimulants and amoxetine.

Dr. Childress gave an overview of ADHD treatment- Attachment.

Carson City:

Joe Schaub, Novartis, gave an overview of Ritalin LA and Focalin-Attachment.

Dr. Charles Price, Professor,UNR, with a private practice, stated he was on multiple speakers bureaus and had lectured throughout the county. He then gave an overview of all the medications in this class. Dr. Heard asked about the dopamine and movement disorders. Dr. Price stated modafanil, amoxetine and bupropion do not induce movement disorders. Dr. Britt asked about the pediatric dosing in the modafanil studies. He stated 300mg/day was the optimal dose in his experience.

Jeff Hill, Lilly-Gave an overview of Strattera.

Dr. Heard asked if there is any data on intelligence or weight loss. Mr. Hill responded there was no reliable data pertaining to intelligence and there can be weight loss at the onset of therapy. Dr. Britt asked if there were any studies for children under 6. Mr. Hill responded there were no studies available.

Dr. Tina Lynn, Shire-Gave an overview of Adderall XR.

Dr. Phillips acknowledged Dr. Wiser left at 3:40pm.

Anton Wynn, McNeil, gave an overview of Concerta. Dr. Britt asked if they were coming out with a higher dose. He responded there is submission into the FDA for increased dosing.

Dr. Pintar left at 3:50pm.

Mr. Wyles, FHSC, informed the committee written comment was submitted.

Mr. Wyles, FHSC, gave an overview of the class.

Dr. Heard wanted to know why Provigil should be deferred to the DUR board.

Dr. Horne interjected there are good off label studies for modafanil as an antidepressant and it should not have to go to the DUR board.

Motion: Dr. Horne motioned that all drugs in this class be considered therapeutic alternatives.

Seconded: Dr. Heard

Vote: Ayes: Unanimous (Dr. Pintar and Dr. Wiser were absent at this vote)

Motion carried.

VII. Long-Acting Narcotics

Public Comment:

Las Vegas: None

Carson City:

Barry Elliot Cole, American Academy of Pain Management, stated he had received educational grants from Abbott, Ortho and Purdue. He also stated he was a practicing pain consultant at Kaiser Permanente in Honolulu. He stated there should be choices and that education in pain management for prescribers was an important component of pain therapy.

Todd Nicosy, Jansen-Gave an overview of Duragesic.

Dr. Monaghan, FHSC, gave a comparative overview of the class.

Motion: Dr. Horne motioned the drugs in this class are therapeutic alternatives.

Seconded: Ms. Bond

Vote: Ayes: Unanimous (Dr. Wiser and Dr. Pintar absent at this vote)

Motion carried.

VIII. Review of July 14th Meeting Location, Date and Time

The meeting will be held in Carson City with videoconferencing to Las Vegas. The meeting will be held from 12:00 noon to 4:30pm.

Dr. Phillips requested that a summation of the decisions in each drug class be submitted with the recommendations from the state and First Health Services.

IX. Public Comment

None

X. Adjournment

Meeting adjourned at 4:20pm